Lv42
530 积分 2025-04-08 加入
Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies
2小时前
已完结
Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studies
5天前
已完结
Replacing concurrent controls with virtual control groups in rat toxicity studies
5天前
已完结
Recovery Animals in Toxicology Studies: An Innovation and Quality Consortium Perspective on Best Practices With Case Study Examples
5天前
已完结
Historical Control Data
6天前
已完结
Strategies to reduce the use of non-human primates in the development of oncology therapeutics: CD3-bispecifics
29天前
已完结
Impurity Qualification Requirements for Drug-Linkers Related Impurities Used to Generate Antibody-Drug Conjugates
29天前
已完结
Background Lesions in Laboratory Animals
29天前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
1个月前
已完结
皖公网安备34019202002308
